Huang Jessie, Phu Jack, Kalloniatis Michael, Zangerl Barbara
Centre for Eye Health and School of Optometry and Vision Science, University of New South Wales, Kensington, New South Wales, Australia.
Optom Vis Sci. 2020 Feb;97(2):86-93. doi: 10.1097/OPX.0000000000001478.
Icare HOME rebound tonometry is increasingly adopted into clinical practice for IOP phasing of glaucoma patients and suspects. Because of measurement differences with applanation tonometry and diurnal fluctuations, interpretation of the IOP measured with Icare HOME phasing can be challenging.
The purpose of this study was to use a large patient cohort to develop a practical, analytical tool for interpreting Icare HOME measurements with respect to applanation pressure.
IOP measurements using the Icare HOME and an applanation tonometer were taken prospectively in 498 consecutive patients. Bland-Altman, frequency distribution, and linear regression analysis were applied to determine measurement differences. A novel criterion, Threshold Icare HOME IOP, was developed to assist identification of elevation above target applanation pressure, considering the expected diurnal variation and measurement variability.
Icare HOME tended to underestimate applanation tonometry (mean bias, -1.7 mmHg; 95% limits of agreement, -7.0 to +3.6). Overall, differences were within ±3 mmHg in 71.5% and ±5 mmHg in 92% of patients. Based on the novel criterion developed, Icare HOME measurements that exceed target applanation pressure by 6 mmHg or greater are generally outside the 95% limit of expected observations.
The Threshold Icare HOME IOP is a novel and practical criterion that can assist clinicians in their interpretation of Icare HOME phasing measurements with respect to target applanation pressures. Elevation above the expected thresholds may prompt closer monitoring or even modifications to glaucoma management.
Icare HOME回弹眼压计越来越多地被应用于青光眼患者及疑似患者眼压监测的临床实践中。由于与压平眼压计的测量差异以及昼夜波动,对Icare HOME眼压监测结果的解读具有挑战性。
本研究旨在利用一个大型患者队列开发一种实用的分析工具,用于解读Icare HOME眼压测量值与压平眼压之间的关系。
前瞻性地对498例连续患者使用Icare HOME眼压计和压平眼压计进行眼压测量。采用Bland-Altman分析、频率分布分析和线性回归分析来确定测量差异。考虑到预期的昼夜变化和测量变异性,制定了一个新的标准——Icare HOME眼压阈值,以协助识别高于目标压平眼压的眼压升高情况。
Icare HOME眼压计倾向于低估压平眼压计测量值(平均偏差为-1.7 mmHg;95%一致性界限为-7.0至+3.6)。总体而言,71.5%的患者测量差异在±3 mmHg以内,92%的患者在±5 mmHg以内。根据制定的新标准,Icare HOME测量值超过目标压平眼压6 mmHg或更多时,通常超出预期观察值的95%界限。
Icare HOME眼压阈值是一种新颖实用的标准,可协助临床医生解读Icare HOME眼压监测测量值与目标压平眼压的关系。高于预期阈值可能提示需要更密切的监测,甚至调整青光眼治疗方案。